HEOR Technical Portfolio
  • Home
  • Flagship Audits
    • NICE TA975 (CAR-T) Case
    • ML-NMR: AML Population Alignment
    • RWE ECA: R/R DLBCL
    • PSM: Survival Extrapolation in RRMM
    • NICE TA1092 (Pembro) Case
    • Multinomial NMA: Response in RRMM
  • NMA Library
    • Bayesian Estimation
    • Standard Bayesian NMA
    • Network Meta-Regression
    • Survival NMA
    • Component NMA
    • IPD NMA
    • MAIC
    • STC
    • ML-NMR
    • Flexible Survival
    • HR vs OR Intuition
  • RWE Library
    • NICE Framework & Confounding
    • PSM, IPTW & AIPW
    • TMLE & Sensitivity Analysis
    • Survival & Immortal Time
  • Replication & Verification
    • Markov CEA: Hypertension verification
    • BIM rebuild: Venetoclax in AML
  • Methodology Wiki

Xiaoge Zhang, PhD

HEOR Technical Portfolio & Knowledge Base

Bridging Academic Econometrics with Industrial HTA Standards

A professional showcase of high-fidelity health economic modeling, Bayesian evidence synthesis, and real-world causal inference, tailored for advanced HTA applications and NICE/SMC submissions.

LinkedIn View CV


πŸš€ Flagship Case Studies

Replicating a Published Multinomial NMA

Response rates in relapsed/refractory myeloma β€” van Beurden-Tan et al. 2022 (BMC Cancer, CC-BY)

A Bayesian multinomial network meta-analysis over 17 phase III trials and 16 treatments, rebuilt in Stan from the published trial counts and cross-checked by running the original WinBUGS code in JAGS. All sixteen response rates reconcile to within 0.27 percentage points and SUCRA to within 0.2 β€” but only after correcting the data file the paper supplies for replication, which produces an error of 19.6 points as published. The rebuild then asks what the ranking rests on: the treatment reported as best holds 47% of the posterior probability of being best, and loses that place when an undiscussed continuity constant or the prior width is changed.

View the replication β†’

NICE TA1092 (Pembro) Case Study

Mock Case β€” Extrapolation Audit & Spline Sensitivity

An EAG-style forensic audit of survival extrapolations (standard parametric vs. flexible splines), treatment-effect waning (5-7 years), and curve-crossing capping, using Guyot-reconstructed patient-level data.

View Case Study β†’

NICE TA975 (CAR-T) Case Study

Full Submission Replication

A complete end-to-end reconstruction of a CAR-T therapy appraisal (Tisagenlecleucel). Features state-transition modeling, parametric survival fitting, and ICER calculations via Patient Access Schemes (PAS).

View Case Study β†’

ML-NMR: AML Population Alignment (TA1013)

Mock Case β€” Population Alignment & Synthesis

A synthetic-data deep dive into Multilevel Network Meta-Regression. Solves the β€œExtrapolation Gap” using 64-point Sobol integration and Cholesky decomposition to bridge IPD and AgD seamlessly in a Bayesian framework.

View ML-NMR Report β†’

RWE External Control Arm: R/R DLBCL

Mock Case β€” Doubly Robust Causal Inference Pipeline

A synthetic-data methodological showcase of External Control Arm construction for a fictional NICE appraisal. Implements IPTW, TMLE (doubly robust estimation), and E-value sensitivity analysis β€” aligned with the NICE RWE Framework (2022).

View Case Study β†’

PSM: Survival Extrapolation in RRMM

Mock Case β€” Treatment Effect Waning & Recursive Hazard Chaining

A synthetic-data deep dive into long-term survival extrapolation in a Partitioned Survival Model. Contrasts Naive HR Switching (the Hazard Cliff) against Recursive Hazard Chaining, with full cost-effectiveness analysis and PSA.

View Case Study β†’


πŸ” Replication & Verification

Published models rebuilt from their own papers, reproduced number by number, and then checked β€” against the source data, against the reporting, and against the verification standards the field already has.

Verifying a Published Hypertension Markov Model

Cost-effectiveness of two antihypertensive regimens in China β€” Feng et al. 2023 (J Int Med Res, CC BY-NC)

A four-state Markov cost-effectiveness model rebuilt in R from the published inputs and checked stage by stage against the TECH-VER verification checklist. The published QALYs reproduce exactly and both arms’ costs reconcile β€” the amlodipine arm only once its drug price is taken from the paper’s own Figure 4 rather than its Table 2, which differ by 35 CNY a year. The trial percentages behind the transition matrix are cumulative over a 36-month follow-up and are used as one-year probabilities: run the model over the trial’s own three years and it returns 11.2% cumulative death where 4.1% went in. Correcting that halves the health gain, and the direction of the published conclusion survives while its magnitudes do not.

View the verification β†’

Rebuilding a Published Budget Impact Model

Venetoclax in AML β€” a replication of Palacios et al. 2024 (PLoS One, CC-BY)

A three-year budget impact model for venetoclax combinations in acute myeloid leukaemia, reconstructed from Palacios et al. (PLoS One 2024, CC-BY) rather than restated: epidemiology funnel, market share in both worlds, six cost components built from published quantities, and a one-way sensitivity analysis run on the parameters the source itself varied. Every input names where it came from β€” a trial, the Delphi panel, a national price list, or an explicit assumption β€” and the year-3 result reconciles to within 0.1% of the published figure under both payer perspectives.

A working deliverable would be an Excel workbook; this page exists to make the structure and its judgements visible.

Open the model β†’


πŸ“š The Technical Library

NMA & Evidence Synthesis Library

A comprehensive suite of technical guidelines and code templates for diverse Network Meta-Analysis challenges.

Fundamentals

Bayesian Estimation Basics HR vs OR Intuition Standard Bayesian NMA

Population Adjust

MAIC Framework STC Methodology ML-NMR Framework

Advanced Synthesis

Survival NMA Network Meta-Regression Component NMA IPD NMA

Real-World Evidence & Causal Inference Library

Methodological guidelines and implementation templates for causal inference, confounding adjustment, and external control arms.

RWE Methodology

A focused library of methodological frameworks, implementation guides, and causal inference templates for observational studies, aligned with the 2022 NICE RWE Framework.

Technical Guides

NICE RWE Framework & Confounding Propensity Score Methods (PSM, IPTW, AIPW) TMLE & E-Value Sensitivity Analysis Survival Analysis & Immortal Time Bias


πŸ› οΈ Tech Stack & Methodologies

R (HEEMOD, multinma, tidyverse) Stan / Bayesian Inference Excel (VBA / PowerQuery) NICE DSU TSD Guidelines SuperLearner / TMLE